Number of the records: 1

Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors

SYSNO ASEP	0353545
Document Type	P - Patent
R&D Document Type	Patent or other outcome protected by special legislation
Title	Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors
Author(s)	Fuksová, Květa (UEB-Q) Havlíček, Libor (UEB-Q)_{RID, ORCID} Kryštof, Vladimír (UEB-Q)_{RID, ORCID} Lenobel, René (UEB-Q)_ORCID Strnad, Miroslav (UEB-Q)_{RID, ORCID}
Year of issue	2010
Possible third party use of the result	A - Pro využití výsledku jiným subjektem je vždy nutné nabytí licence
Royalty requested	A - Poskytovatel licence požaduje licenční poplatek
Patent no. or utility model no. or industrial design no.	US7816350
Date of the patent acceptance	19.10.2010
Name of the patent owner	Ústav experimentální botaniky AV ČR, v. v. i., Univerzita Palackého v Olomouci
Current use	B - Patent je využíván na základě uzavřené licenční smlouvy mezi vlastníkem a uživatelem
Language	eng - English
Country	US - United States
Keywords	Substituted [1,2,3]triazolo[4,5-D]pyrimidines ; CDK ; inhibitors
Subject RIV	FD - Oncology ; Hematology
R&D Projects	GA301/08/1649 GA ČR - Czech Science Foundation (CSF)
	KAN200380801 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR)
Annotation	The present invention relates to a compound of formula I, or a pharmaceutically acceptable acid salt thereof. The invention further relates to the use of such compounds in the treatment of hyperproliferative skin disorders, viral infections, cancer, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft versus host disease and gout, or for psoriasis, parasitoses such as those caused by fungi or protists, or Alzheimer's disease.Further aspects of the invention relate to the use of such compounds in the inhibition of cell proliferation, in the induction of apoptosis, to modulate the activity of adrenergic and/or purinergic receptors or to suppress immunostimulation. The invention also relates to the use of 2,6,9-trisubstituted 8-azapurines in maintaining mammalian ooctyes at the germinal vesicle stage.
Workplace	Institute of Experimental Botany
Contact	David Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469
Year of Publishing	2011

Number of the records: 1